RxPack is a leading manufacturer of advanced pharmaceutical dispensing solutions, specializing in pMDIs and inhalation Drug Delivery Systems designed to meet the industry’s evolving environmental and regulatory expectations. With decades of expertise in aerosol and spray technologies, RxPack delivers robust, high‑performance pMDI platforms that are fully compatible with next‑generation low GWP propellants, including HFA‑152a and HFO1234ze, both of which are central to the industry’s transition toward greener inhalation therapies.

RxPack’s pMDI metering valves offer a wide dosage range, demonstrating excellent sealing, low moisture ingress, and reliable performance for both solution and suspensions. The valves are specifically engineered to support the shift from traditional propellants to modern lower‑impact alternatives, ensuring consistent delivery, device integrity, and compatibility throughout development and scale‑up.

To help pharmaceutical companies navigate the transition to sustainable propellants, RxPack provides end‑to‑end technical, regulatory, and manufacturing support—from early‑stage formulation guidance through industrialization and full‑scale production. This integrated approach minimizes development risk, accelerates time‑to‑market, and ensures a smooth, compliant, and successful transition.

At RDD 2026, RxPack presents itself as a strategic partner for companies aiming to future‑proof their respiratory portfolios while maintaining the highest standards of device performance, patient usability, and regulatory readiness.